Brain Metastases News

Surgery, RT Similar for Control of Brain Metastases - MedPage Today



MedPage Today
 
Surgery, RT Similar for Control of Brain Metastases 
MedPage Today
SAN DIEGO -- Radiosurgery and neurosurgery provided similar local disease control when provided as initial therapy for limited brain metastasis, a retrospective analysis of a randomized trial showed. Overall, stereotactic radiosurgery (SRS) was ...

 


Managing Brain Metastases in Melanoma - OncLive



OncLive
 
Managing Brain Metastases in Melanoma 
OncLive
Panelists: Jeffrey S. Weber, MD, PhD, NYU Langone Health; Reinhard G. Dummer, MD, University Hospital of Zurich; Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein; Michael A. Postow, MD, Memorial Sloan Kettering Cancer Center; ...

 


Pfizer next-gen ALK inhibitor could ease lung cancer burden - BioPharma Dive



Market Exclusive
 
Pfizer next-gen ALK inhibitor could ease lung cancer burden 
BioPharma Dive
Xalkori has been bested by Roche's Alecensa (alectinib) in a Phase 3 head-to-head study in ALK-positive non-small cell lung cancer, including prevention of brain metastases. Alecensa has accelerated approval for NSCLC patients who previously failed on ...
Pfizer's lorlatinib impresses in Phase II lung cancer trial PharmaTimes
Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC OncLive
Pfizer Inc. (NYSE:PFE) Phase II Clinical Trial Of Lorlatinib Shows Promise Market Exclusive

all 6 news articles » 


New Data Supports Safety and Efficacy of Alunbrig in Lung Cancer - Rare Disease Report (blog)



Rare Disease Report (blog)
 
New Data Supports Safety and Efficacy of Alunbrig in Lung Cancer 
Rare Disease Report (blog)
I am especially encouraged by the efficacy seen in patients with brain metastases, cancer that has spread to the brain. The central nervous system is a common site for progression in this disease, with brain metastases occurring in up to 70 percent of ...
Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG (brigatinib) in ALK-Positive Non ... New Kerala

all 2 news articles » 


Discovery of Novel Targets in Brain Metastases Benefits Patients - LWW Journals



Discovery of Novel Targets in Brain Metastases Benefits Patients 
LWW Journals
Identifying novel drivers of metastatic cancer and taking that knowledge back to the clinic is the stuff of professional life for Priscilla Brastianos, MD. But this physician scientist, a native of Vancouver, British Columbia, also works to meet ...

 


Pfizer's son of Xalkori impresses in phase 2 NSCLC trial - FierceBiotech



FierceBiotech
 
Pfizer's son of Xalkori impresses in phase 2 NSCLC trial 
FierceBiotech
Investigators enrolled 275 ALK or ROS1-positive NSCLC patients with or without asymptomatic, untreated or treated brain metastases. The patients had undergone varying degrees of treatment before joining the study. Once in the trial, they received 100mg ...
Trial Shows Strong Response to Lorlatinib in NSCLC Patients Managed Care magazine

all 5 news articles » 


Scientist's funding boost to help treat secondary cancer - Oxfordshire Guardian (blog)



Oxfordshire Guardian (blog)
 
Scientist's funding boost to help treat secondary cancer 
Oxfordshire Guardian (blog)
Professor Sibson, professor of imaging neuroscience at the university, said: ?We urgently need to find ways to treat brain metastases [secondary growth] more effectively and improve survival rates. ?With this funding from Breast Cancer Now our aim is ...

and more » 


Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly ... - GlobeNewswire (press release)



Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly ... 
GlobeNewswire (press release)
Additional planned studies include Phase 2 trials in pancreatic cancer and brain metastases, with study initiation subject to receipt of additional funding or collaborative partnering. The Company also believes that TSC has potential application in ...

and more » 


Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC - OncLive



OncLive
 
Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC 
OncLive
A lower dose of ceritinib (Zykadia) taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal (GI) adverse events (AEs) versus a 750-mg dose taken without food for patients with untreated ALK-positive ...

 


Promising Phase 1/2 Results for entrectinib Against ROS1+ Non-small Cell Lung Cancer - PR Web (press release)



PR Web (press release)
 
Promising Phase 1/2 Results for entrectinib Against ROS1+ Non-small Cell Lung Cancer 
PR Web (press release)
For these patients, we've been using targeted radiation and other strategies to try to control brain metastases while continuing to target ROS1 in the body. We are hopeful that entrectinib will help us control many cases of ROS1+ cancer in both the ...

and more »